2017年6月,欧盟批准nivolumab(Opdivo)用于转移性尿路上皮癌(mUC)的治疗,这也是该药在欧盟获批的第8个适应证。膀胱癌是欧洲第五大常见癌症,每年诊断的新病例约151 000例,每年有超过52 000例病例死亡。本品的批准是基于名为Check Mate-275的Ⅱ期临床研究的数据,该研究共纳入270例既往接受过铂类药 In June 2017, the European Union approved nivolumab (Opdivo) for the treatment of metastatic urothelial carcinoma (mUC), the eighth indication of its approval in the European Union. Bladder cancer is the fifth most common cancer in Europe with about 151,000 new cases diagnosed each year and over 52,000 deaths each year. This product is approved based on data from a Phase II clinical study called Check Mate-275, which included 270 previously treated platinum-based drugs